Immunization with a dominant-negative recombinant Herpes Simplex Virus HSV type 1 protects against HSV-2 genital disease in guinea pigsReportar como inadecuado




Immunization with a dominant-negative recombinant Herpes Simplex Virus HSV type 1 protects against HSV-2 genital disease in guinea pigs - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Microbiology

, 10:163

First Online: 03 June 2010Received: 06 February 2010Accepted: 03 June 2010

Abstract

BackgroundCJ9-gD is a novel dominant-negative recombinant herpes simplex virus type 1 HSV-1 that is completely replication-defective, cannot establish detectable latent infection in vivo, and expresses high levels of the major HSV-1 antigen glycoprotein D immediately following infection. In the present study, CJ9-gD was evaluated as a vaccine against HSV-2 genital infection in guinea pigs.

ResultsAnimals immunized with CJ9-gD developed at least 700-fold higher titers of HSV-2-specific neutralization antibodies than mock-immunized controls. After challenge with wild-type HSV-2, all 10 control guinea pigs developed multiple genital lesions with an average of 21 lesions per animal. In contrast, only 2 minor lesions were found in 2 of 8 CJ9-gD-immunized animals, representing a 40-fold reduction on the incidence of primary genital lesions in immunized animals p < 0.0001. Immunization significantly reduced the amount and duration of viral shedding and provided complete protection against neurological symptoms, while 90% of mock-immunized animals succumbed due to the severity of disease. Importantly, immunized animals showed no signs of recurrent disease or viral shedding during a 60-days observation period after recovery from primary infection, and carried 50-fold less latent viral DNA load in their dorsal root ganglia than the surviving mock-vaccinated controls p < 0.0001.

ConclusionsCollectively, we demonstrate that vaccination with the HSV-1 recombinant CJ9-gD elicits strong and protective immune responses against primary and recurrent HSV-2 genital disease and significantly reduces the extent of latent infection.

AbbreviationsHSVHerpes simplex virus

gDGlycoprotein D.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2180-10-163 contains supplementary material, which is available to authorized users.

Richard Brans contributed equally to this work.

Download fulltext PDF



Autor: Richard Brans - Feng Yao

Fuente: https://link.springer.com/article/10.1186/1471-2180-10-163







Documentos relacionados